血清白介素-1β和乳酸脱氢酶在卵巢上皮性癌患者中的表达及意义
|
摘要
目的探讨卵巢上皮性癌(EOC)患者血清中白介素-1β(IL-1β)和乳酸脱氢酶(LDH)的表达及临床意义。方法采用酶联免疫吸附法(ELISA)检测收集2015年1月至2016年12月兰州大学第一医院妇产科收治的卵巢上皮性癌组、良性卵巢肿瘤组和正常对照组共268例受试者血清中IL-1β和LDH表达水平,及其与EOC患者间的临床病理及预后的关系。结果卵巢上皮性癌组患者血清中IL-1β和LDH含量水平显著高于良性卵巢肿瘤组和正常对照组(P <0.05);IL-1β和LDH高表达与EOC患者肿瘤分级、临床分期及盆腹腔淋巴结转移密切相关,IL-1β和LDH是影响EOC患者预后的独立风险因素(P <0.05)。结论 IL-1β和LDH表达水平与EOC进展及预后有关,IL-1β和LDH高表达可作为EOC患者不良预后的重要指标。
Objective To investigate the clinical significance of serum interleukin-1β(IL-1β) and lactic dehydrogenase(LDH) in epithelial ovarian cancer(EOC).Methods The serum level of IL-1β and LDH were detected by ELISA in EOC group,healthy controls and patients with other benign ovarian tumor in 268 patients from January 2015 to December 2016 admitted to the department of obstetrics and gynecology of the First Hospital of Lanzhou University.The correlation between expression of IL-1β/LDH and prognosis of EOC patients were analyzed.Results The serum levels of IL-1β and LDH in EOC patients were signif icantly higher than those in patients with other benign ovarian diseases and normal controls(P <0.05).The expressions of IL-1β and LDH were signif icantly correlated with grade,clinical stage and pelvic lymph node metastasis of EOC(P <0.05).Further analysis by Cox proportional hazard regression model showed that the high levels of IL-1β and LDH expression were signif icantly independent hazard factors for overall survival in EOC(P<0.05).Conclusion IL-1β and LDH expression levels are closely related to the progression and prognosis of EOC.High expression levels of IL-1β and LDH may be used as the important indicators of poor prognostic in EOC patients.
Objective To investigate the clinical significance of serum interleukin-1β(IL-1β) and lactic dehydrogenase(LDH) in epithelial ovarian cancer(EOC).Methods The serum level of IL-1β and LDH were detected by ELISA in EOC group,healthy controls and patients with other benign ovarian tumor in 268 patients from January 2015 to December 2016 admitted to the department of obstetrics and gynecology of the First Hospital of Lanzhou University.The correlation between expression of IL-1β/LDH and prognosis of EOC patients were analyzed.Results The serum levels of IL-1β and LDH in EOC patients were signif icantly higher than those in patients with other benign ovarian diseases and normal controls(P <0.05).The expressions of IL-1β and LDH were signif icantly correlated with grade,clinical stage and pelvic lymph node metastasis of EOC(P <0.05).Further analysis by Cox proportional hazard regression model showed that the high levels of IL-1β and LDH expression were signif icantly independent hazard factors for overall survival in EOC(P<0.05).Conclusion IL-1β and LDH expression levels are closely related to the progression and prognosis of EOC.High expression levels of IL-1β and LDH may be used as the important indicators of poor prognostic in EOC patients.
引文
[1]Verdoodt F, Dehlendorff C, Friis S, et al. Non-aspirin NSAID use and ovarian cancer mortality[J]. Gynecol Oncol, 2018, 150(2):331-337.
[2]凌存保,吴隽松.乳腺癌患者血清IL-6、IL-1β、TNF-ɑ的变化及其临床意义[J].标记免疫分析与临床, 2014, 21(5):532-534.
[3]Liu L, Cao L, Gong B, et al. Novel biomarkers for the identification and targeted therapy of gastric cancer[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(9):1217-1226.
[4]Byers LA, Rudin CM, Small cell lung cancer:where do we go from here?[J]. Cancer, 2015, 121(5):664-672.
[5]郭艺红,孙莹璞,乔玉环等。多囊卵巢综合征患者卵泡液LIF、IL-1β及性激素水平与IVF-ET结局关系的研究[J].生殖与避孕, 2004, 26(4):344-348.
[6]Zhang X, Guo M, Fan J, et al.Prognostic significance of serum LDH in small cell lung cancer:A systematic review with metaanalysis[J]. Cancer Biomark, 2016, 16(3):415-423.
[7]Grignani G, D'Ambrosio L, Pignochino Y, et al. Trabectedin and olaparib in patients with advanced and non-resectable bone and softtissue sarcomas(TOMAS):an open-label, phase 1b study from the Italian Sarcoma Group[J]. Lancet Oncol, 2018, 19(10):1360-1371.
[8]Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation andcolorectalcancer[J]. Intest Res, 2018, 16(3):338-345.
[9]KaiH,KitadaiY,KodamaM,etal.Involvementof proinflammatory cytokines IL-1 beta and IL-6 in progression of human gastriccarcinoma[J]. Anticancer Res, 2005, 25(2A):709-13.
[10]Syed SN, Jung M, Weigert A, et al. S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such asIL-1βor Lipocalin-2[J]. Mediators Inflamm, 2017;2017:7510496.
[11]许海. 50例卵巢癌患者IL-1β分子生物学表达的相关性研究[J].现代肿瘤医学, 2012, 20(3):593-594.
[12]徐鸾荀,王健,雷群英.糖代谢异常与肿瘤发化发展[J].中固生化药物杂志, 2016, 36(09):11-15.
[13]De Francesco EM, Maggiolini M, Musti AM. Crosstalk between Notch, HIF-1αand GPER in Breast Cancer EMT[J]. Int J Mol Sci, 2018, 19(7).
[14]彭彦,王燕,李峻岭,等.血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用[J].中国肺癌杂志, 2016, 19(9):590-594.
[15]Yin S, Lan C, Pei H, et al. Expression of interleukin 1βgastric cancer tissue and its effects on gastric cancer[J]. Onco Targets Ther, 2016, 9:31-35.
[16]Sieow JL, Gun SY, Wong SC. The sweet surrender:how myeloid cell metabolic plasticity shapes the tumor microenvironment[J].Front Cell Dev Biol. 2018, 6:168.
[17]Chen MF, Lin PY, Wu CF, et a1.IL-6 expression regtdates tumorigenicity and correlates with prognosis in bladder cancer[J]. PLoS One, 2013, 8(4):e61901.
[18]Meng S, Gui Q, Xu Q, et al. Association of Shp 2 with phosphorylated IL-22 is required for interleukin-22-induced MAP kinase activation[J]. J Mol Cell Biol, 2010, 2(4):223-230.
[19]Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8(IL-8)levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients[J]. Ann Oncol, 2017, 28(8):1988-1995.
[20]李博.肿瘤糖代谢紊乱的研究进展和探索[J].中山大学学报, 2017, 38(2):222-227.
[2]凌存保,吴隽松.乳腺癌患者血清IL-6、IL-1β、TNF-ɑ的变化及其临床意义[J].标记免疫分析与临床, 2014, 21(5):532-534.
[3]Liu L, Cao L, Gong B, et al. Novel biomarkers for the identification and targeted therapy of gastric cancer[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(9):1217-1226.
[4]Byers LA, Rudin CM, Small cell lung cancer:where do we go from here?[J]. Cancer, 2015, 121(5):664-672.
[5]郭艺红,孙莹璞,乔玉环等。多囊卵巢综合征患者卵泡液LIF、IL-1β及性激素水平与IVF-ET结局关系的研究[J].生殖与避孕, 2004, 26(4):344-348.
[6]Zhang X, Guo M, Fan J, et al.Prognostic significance of serum LDH in small cell lung cancer:A systematic review with metaanalysis[J]. Cancer Biomark, 2016, 16(3):415-423.
[7]Grignani G, D'Ambrosio L, Pignochino Y, et al. Trabectedin and olaparib in patients with advanced and non-resectable bone and softtissue sarcomas(TOMAS):an open-label, phase 1b study from the Italian Sarcoma Group[J]. Lancet Oncol, 2018, 19(10):1360-1371.
[8]Park CH, Eun CS, Han DS. Intestinal microbiota, chronic inflammation andcolorectalcancer[J]. Intest Res, 2018, 16(3):338-345.
[9]KaiH,KitadaiY,KodamaM,etal.Involvementof proinflammatory cytokines IL-1 beta and IL-6 in progression of human gastriccarcinoma[J]. Anticancer Res, 2005, 25(2A):709-13.
[10]Syed SN, Jung M, Weigert A, et al. S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such asIL-1βor Lipocalin-2[J]. Mediators Inflamm, 2017;2017:7510496.
[11]许海. 50例卵巢癌患者IL-1β分子生物学表达的相关性研究[J].现代肿瘤医学, 2012, 20(3):593-594.
[12]徐鸾荀,王健,雷群英.糖代谢异常与肿瘤发化发展[J].中固生化药物杂志, 2016, 36(09):11-15.
[13]De Francesco EM, Maggiolini M, Musti AM. Crosstalk between Notch, HIF-1αand GPER in Breast Cancer EMT[J]. Int J Mol Sci, 2018, 19(7).
[14]彭彦,王燕,李峻岭,等.血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用[J].中国肺癌杂志, 2016, 19(9):590-594.
[15]Yin S, Lan C, Pei H, et al. Expression of interleukin 1βgastric cancer tissue and its effects on gastric cancer[J]. Onco Targets Ther, 2016, 9:31-35.
[16]Sieow JL, Gun SY, Wong SC. The sweet surrender:how myeloid cell metabolic plasticity shapes the tumor microenvironment[J].Front Cell Dev Biol. 2018, 6:168.
[17]Chen MF, Lin PY, Wu CF, et a1.IL-6 expression regtdates tumorigenicity and correlates with prognosis in bladder cancer[J]. PLoS One, 2013, 8(4):e61901.
[18]Meng S, Gui Q, Xu Q, et al. Association of Shp 2 with phosphorylated IL-22 is required for interleukin-22-induced MAP kinase activation[J]. J Mol Cell Biol, 2010, 2(4):223-230.
[19]Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8(IL-8)levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients[J]. Ann Oncol, 2017, 28(8):1988-1995.
[20]李博.肿瘤糖代谢紊乱的研究进展和探索[J].中山大学学报, 2017, 38(2):222-227.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |